Psoriasis Vulgaris Clinical Trial
— LPA-01Official title:
A Preliminary Study on the Effect of Photothermal Laser Therapy on the Vascularization and Innervation of Psoriatic Lesions
Verified date | January 2024 |
Source | ZBC MultiCare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The researchers investigate the effect of a treatment with selective photothermolysis using a 595 nm pulsed dye laser on the blood vessel density and the nerve fibre density of a psoriatic lesion. By comparing tissue samples collected before and after two treatments, the researchers determine the relative effect of laser therapy on the (hyper)innervation of psoriatic skin.
Status | Active, not recruiting |
Enrollment | 22 |
Est. completion date | July 31, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 69 Years |
Eligibility | Inclusion Criteria: - 18 - 69 years of age - Psoriasis vulgaris - Skin type I - III - Minimal surface of lesion of 3 cm2 - Contralateral psoriasis vulgaris lesions located on chest, back, or upper legs Exclusion criteria A potential subject who meets any of the following criteria will be excluded from participation in this study if: - The participant uses other treatments (than laser therapy) during the study or two weeks before the start of the study that are known to affect psoriasis - The participant suffers from any known neurological, vascular, or immunological condition other than psoriasis. - The participant is allergic to lidocaine |
Country | Name | City | State |
---|---|---|---|
Netherlands | ZBC MultiCare | Hilversum | Noord-Holland |
Lead Sponsor | Collaborator |
---|---|
Nick van der Beek | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recovery ration | Relative change in the ratio of the linear nerve density and linear blood vessel density. | 6 months. | |
Secondary | Recovery ratio vs lymphocyte infiltration | Correlation between change in the ratio of the linear nerve density and linear blood vessel density versus change in number of infiltrating lymphocytes | 6 months | |
Secondary | Clinical improvement | Change in severity determined using a visual-analogue scale. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
Completed |
NCT06064084 -
Incretin Effect in Patients With Psoriasis and Controls
|
||
Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 |